Morepen Laboratories Ltd.

₹115.78

0.5 (0.4%)

MOREPENLAB Share Price

Pharmaceuticals & Biotechnology

As on September 11, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 6,361 Cr

P/E Ratio66.86

Dividend Yield0.09 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	116.73	Bearish
10-DMA	113.76	Bullish
20-DMA	104.29	Bullish
50-DMA	80.21	Bullish
100-DMA	63.5	Bullish
200-DMA	51.61	Bullish

Historical Performance

1 Year

113.9%

3 Years

197.6%

5 Years

107.7%

10 Years

372.6%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	18,057	18,116	16,904	14,175	15,468
Total Expenditure	16,801	16,375	15,318	13,380	14,102
Other Income	213	184	140	61	201
Operating Profit	1,469	1,924	1,726	857	1,568
Interest	164	83	37	20	24
Depreciation	364	290	335	279	276
Profit Before Tax	1,199	1,551	1,354	558	1,267
Consolidated Net Profit	949	1,180	962	387	1,017
Adjusted EPS	2	2	2	1	2

Compounded Sales Growth

10 Years:30.1

5 Years:8.7

3 Years:5

TTM:-0.1

Compounded Profit Growth

10 Years:49.3

5 Years:-0.5

3 Years:19.7

TTM:-4.3

Stock Price CAGR

10 Years:17.4

5 Years:14.5

3 Years:45.5

TTM:114.9

Return on Equity

10 Years:0.5

5 Years:2.1

3 Years:1.9

last year:1.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	1,096	1,096	1,022	1,022	956
Total Reserves	11,369	10,466	7,450	6,507	4,568
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	1,987	905	439	369	355
Other Current Liabilities	1,065	717	585	549	1,700
Short Term Borrowings	370	460	235	232	161
Total Liabilities	19,361	17,781	12,932	11,105	10,700
Capital Work in Progress	216	283	245	170	141
Long Term Loans & Advances	1,364	945	708	701	695
Currents Investments	229	778	---	---	---
Short Term Loans and Advances	3,604	3,360	2,470	2,006	1,565
Total Current Assets	11,636	11,594	8,890	7,562	7,343
Total Assets	19,361	17,781	12,932	11,105	10,700
Adjusted Book Value	23	21	17	15	12

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 66.86, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 45.5%, indicating sustained price appreciation.
The stock carries a high beta of 1.5, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹1469 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹18057 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 2161687.8

No. of Shares: 18671 (Approx)

Performance:116.2%

1161687.8

NIFTY Performance: -6.8%

1 day Top Gainers